28 Feb 2022 by admin in UncategorizedComments Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTACTM Molecule for Friedreich Ataxia
16 Feb 2022 by admin in UncategorizedComments Walking Fish Therapeutics Closes $73 Million Series A Financing
08 Feb 2022 by admin in UncategorizedComments Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
02 Feb 2022 by admin in UncategorizedComments Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
01 Feb 2022 by admin in UncategorizedComments Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
28 Jan 2022 by admin in UncategorizedComments Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
17 Jan 2022 by admin in UncategorizedComments Eluminex Biosciences Successfully Completes Its First Pre-IND Meeting with the United States Food and Drug Administration for a Multivalent Fc Fusion Protein (EB-101) for the Treatment of Neovascular Age-related Macular Degeneration
10 Jan 2022 by admin in UncategorizedComments Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
10 Jan 2022 by admin in UncategorizedComments BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies
